Rykindo NDA for Schizophrenia, Bipolar Disorder Submitted to FDA - Monthly Prescribing Reference

Rykindo NDA for Schizophrenia, Bipolar Disorder Submitted to FDA  Monthly Prescribing Reference

Luye Pharma Group announced the submission of a New Drug Application (NDA) for Rykindo (risperidone extended-release microsphere; LY03004) for ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases